Insulin efsitora alfa (basal Fc)

Insulin efsitora alfa (formerly "basal insulin Fc" / BIF / LY3209590) is an investigational once-weekly basal insulin from Eli Lilly. It is built by fusing a single-chain insulin variant — engineered with reduced insulin-receptor affinity — to a human IgG2 Fc domain.⁷ The Fc portion lets the molecule ride the body's neonatal Fc receptor (FcRn) recycling pathway, which rescues it from degradation and stretches its action out to a week.⁸ Like all basals, its job is steady background coverage; it does not replace mealtime (bolus) insulin, which people with type 1 diabetes still inject at meals.⁹

PK/PD — the numbers. Efsitora's defining feature is an extraordinarily long, flat profile. Its half-life is roughly 17 days after a single dose and about 19 days at steady state.¹⁰¹¹ Glucose-lowering effect peaks gently around days 4-5 after a dose, and the profile is remarkably even: at steady state the drug-level peak-to-trough ratio is just 1.16, and the glucose-lowering peak-to-trough ratio only 1.07 — essentially a flat line across the week.¹¹ Because of that long half-life, reaching steady state would otherwise take 8-10 weeks, so Lilly uses a one-time loading dose to bring levels up quickly; steady state is then reached between the 4th and 6th weekly dose.¹¹ Within-week exposure varies little, and immunogenicity is very low (treatment-emergent anti-drug antibodies in ~0.6% of type 1 participants), with no measurable effect on clearance, efficacy or safety.¹²

Absorption variability & exercise. The flat depot means little day-to-day swing in background insulin — good for predictability.¹⁰ The trade-off is rigidity: a fixed weekly dose cannot be reduced for a planned active day, illness, or hormonal change. In the type 1 trial, excess lows were concentrated in the first 12 weeks of titration — pointing to dosing, not the molecule, as the challenge.¹³¹⁴

Delivery. Efsitora is given subcutaneously once a week. Lilly has tested fixed doses in a single-use autoinjector pen.¹⁵

Evidence in type 1 diabetes. In the Phase 3 QWINT-5 trial (NCT05463744; 692 adults, 52 weeks), weekly efsitora plus mealtime lispro was non-inferior to daily degludec: HbA1c fell 0.51% vs 0.56% (treatment difference 0.052%).¹³ But combined level 2/3 hypoglycemia was higher with efsitora (14.03 vs 11.59 events per patient-year; rate ratio 1.21), and severe hypoglycemia hit 10% of efsitora users vs 3% on degludec, concentrated in the first 12 weeks.¹³ An earlier Phase 2 trial showed similar HbA1c but higher fasting glucose and slightly lower time-in-range (56.1% vs 58.9%).¹⁶

The meta-analyses now disagree — and we won't paper over it. A 2025 type-1-specific systematic review found comparable HbA1c but a roughly 2.5-fold higher rate of severe hypoglycemia with weekly basals in type 1 diabetes.¹⁷ A June 2026 meta-analysis of five efsitora RCTs (2,562 participants, all comparing against degludec) found no statistically significant difference in hypoglycemia — overall, level 2/3, or nocturnal — in either diabetes type, with an overall HbA1c treatment difference of just 0.08% (95% CI -0.01 to 0.17).⁶ The catch is that the newer analysis pools type 1 and type 2 together, and its type 1 subgroup is small and wide-intervalled (HbA1c treatment difference 0.10%, 95% CI -0.64 to 0.85) — underpowered for exactly the question a person with type 1 is asking. The hard number that has not moved is from QWINT-5 itself: severe hypoglycemia in 10% of efsitora users versus 3% on degludec, concentrated in the first 12 weeks.¹³ Until a properly powered type 1 trial with a refined titration protocol reports, we treat weekly basal insulin in type 1 as an unresolved safety question, not a solved one.

Approvals, access & cost. Efsitora is not yet approved anywhere, but the first regulatory step landed in June 2026: at its 22-25 June meeting the EMA's CHMP adopted a positive opinion recommending EU marketing authorisation for Onswik (efsitora's EU brand name) in adults with type 2 diabetes.¹ A positive opinion is a recommendation, not an approval. Live-checked on 27 August 2026, the EMA page is still at opinion — no European Commission decision has been posted.³ On 20 August 2026 NICE published type-2-only final draft guidance recommending efsitora for NHS use.⁴ A US FDA decision — also type 2 only — is still outstanding in Q3 2026.² Crucially for readers here: neither the EU nor US filing covers type 1 diabetes, and on 30 July 2026 NICE discontinued its separate type 1 appraisal after Lilly said in 2025 it was not pursuing a UK type 1 marketing authorisation.⁵ QWINT-5, the type 1 study, is not part of the EU opinion.¹ Nothing about this changes type 1 access. There is still no price and no biosimilar. Context matters, too: the FDA's advisory committee voted against the rival weekly insulin icodec in type 1 diabetes over hypoglycemia, so the type 1 pathway for weekly basals faces real scrutiny.¹⁸

What's coming. The near-term opportunity is type 2 diabetes, where QWINT-1 and QWINT-3 showed non-inferior HbA1c — and where the first regulatory green light has now arrived in the form of the CHMP's positive opinion.¹³¹⁹¹ That the first recommendation for a once-weekly basal insulin explicitly excludes type 1 diabetes is itself the story: type 1 use will hinge on refined titration protocols to tame the early-weeks hypoglycemia signal.¹³¹⁹ If it is eventually approved for type 1, efsitora would cut basal injections to one per week — a meaningful adherence lever, especially for people who struggle with daily dosing.⁹